Patient Safety Guide for Erdafitinib and Enfortumab Vedotin: What to Look for and What to Report to Your Healthcare Team

Slides on checkpoint inhibitors in first-line, second-line, and maintenance settings for urothelial carcinoma, from Clinical Care Options (CCO)

Cora N. Sternberg, MD, FACP Released: February 26, 2021

Slides on erdafitinib, enfortumab vedotin, and sacituzumab govitecan for progressive urothelial carcinoma, from Clinical Care Options (CCO)

Petros Grivas, MD, PhD Released: February 26, 2021

Downloadable slideset with key highlight data from the virtual 2021 ASCO GU Cancers Symposium provided by Clinical Care Options (CCO)

Robert Motzer, MD Daniel P. Petrylak, MD Released: February 25, 2021

Downloadable slideset from Clinical Care Options (CCO) exploring current and emerging first-line treatment options for patients with metastatic bladder cancer.

Matthew Galsky, MD Released: February 22, 2021